Nuclear Acetyl-CoA Governs Subtelomeric Chromatin State to Set Telomere Length as an Epigenetic Entropy Sensor

Hypothesis

Nuclear acetyl‑coA levels directly modulate histone acetylation at subtelomeric regions, thereby determining telomere chromatin accessibility and influencing the rate of telomere shortening. Low acetyl‑coA promotes a heterochromatic state that increases replication‑associated telomere loss, while elevated acetyl‑coA maintains an euchromatic configuration that buffers telomere attrition. In this view telomere length functions as a readout of epigenetic entropy driven by metabolic flux through the acetyl‑coA pool.

Mechanistic Model

• Acetyl‑CoA production: Cytosolic ACLY converts citrate to acetyl‑CoA, which diffuses into the nucleus; nuclear ACSS2 can also capture extracellular acetate to generate acetyl‑CoA locally.[2]
• Histone acetylation: Acetyl‑CoA serves as the substrate for HATs (p300/CBP, PCAF) that acetylate H3K9 and H3K27 at subtelomeric nucleosomes.[1]
• Chromatin state: High subtelomeric H3K9ac/H3K27ac correlates with open chromatin, facilitating shelterin binding and protecting telomeres from nucleolytic processing. Low acetylation favors HP1 recruitment, heterochromatin spreading, and increased telomere fragility.
• Entropy link: Stochastic fluctuations in acetyl‑CoA concentration create variability in subtelomeric acetylation, which translates into heterogeneous telomere shortening rates across a cell population—a measurable increase in informational entropy.

Testable Predictions

1. Pharmacological elevation of nuclear acetyl‑CoA (via ACLY activator or acetate supplementation) will increase subtelomeric H3K9ac/H3K27ac without altering global histone acetylation patterns.
2. Increased subtelomeric acetylation will correlate with reduced telomere shortening per division in human fibroblasts, measured by single‑telomere length analysis (STELA).
3. Knockdown of ACLY or nuclear ACSS2 will decrease subtelomeric H3K9ac, elevate heterochromatin marks (H3K9me3), and accelerate telomere attrition, even when telomerase activity is unchanged.
4. Rescue of telomere shortening by acetate treatment will be blocked by HAT inhibitors (e.g., C646), confirming dependence on acetylation.
5. Single‑cell multi‑omics will reveal a negative correlation between subtelomeric H3K9ac signal intensity and telomere length heterogeneity across aging cell populations.

Experimental Approach

• Cell model: Human diploid fibroblasts (IMR‑90) and mesenchymal stem cells subjected to replicative senescence.
• Metabolic manipulation: Treat with (i) ACLY activator (SB‑204990), (ii) sodium acetate, (iii) ACLY siRNA, (iv) nuclear‑targeted ACSS2 shRNA.
• Readouts:
  • ChIP‑qPCR for H3K9ac/H3K27ac at subtelomeric regions (primers for D4Z4, telomere‑adjacent repeats).
  • Telomere length by STELA and qPCR‑based T/S ratio.
  • Senescence markers (SA‑β‑gal, p16^INK4a^).
  • Acetyl‑CoA quantification via LC‑MS in nuclear extracts.
• Controls: Global H3K9ac levels to ensure specificity; telomerase activity assay to rule out telomerase‑dependent effects.
• Analysis: Linear regression of subtelomeric acetylation versus telomere shortening rate; entropy calculation using Shannon diversity of telomere length distributions.

If subtelomeric acetylation tracks with telomere shortening independently of telomerase, the hypothesis gains support; lack of correlation would falsify the proposed metabolic‑epigenetic link to telomere length as an entropy metric.